Effects of aggregation of drug and diagnostic codes on the performance of the high-dimensional propensity score algorithm: An empirical example

BMC Medical Research Methodology

Volumn 13, Issue 1, 2013, Pages

  Le, Hoa V ^a,b   Poole, Charles ^a   Brookhart, Alan ^a   Schoenbach, Victor J ^a   Beach, Kathleen J ^b   Layton, J Bradley ^a   Stürmer, Til ^a  

^a University of North Carolina at Chapel Hill   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Aggregation; Anatomical therapeutic chemical classification; Clinical classification software; Confounding by indication; Infrequent exposure; Propensity score; Rare outcome; Small sample

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ADOLESCENT; ADULT; AGED; ALGORITHM; ARTHRITIS; ARTICLE; BLEEDING; CHEMICALLY INDUCED DISORDER; EPIDEMIOLOGY; GASTROINTESTINAL DISEASE; HUMAN; INCIDENCE; MIDDLE AGED; PREVALENCE; PROPENSITY SCORE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STATISTICAL MODEL; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALGORITHMS; ARTHRITIS; CONFOUNDING FACTORS (EPIDEMIOLOGY); CYCLOOXYGENASE 2 INHIBITORS; DICLOFENAC; GASTROINTESTINAL DISEASES; HEMORRHAGE; HUMANS; IBUPROFEN; INCIDENCE; MIDDLE AGED; MODELS, STATISTICAL; PREVALENCE; PROPENSITY SCORE; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SULFONAMIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84887713758     PISSN: None     EISSN: 14712288     Source Type: Journal    
DOI: 10.1186/1471-2288-13-142     Document Type: Article

References (38)

1. Active surveillance of vaccine safety: a system to detect early signs of adverse events. Davis RL, Kolczak M, Lewis E, Nordin J, Goodman M, Shay DK, Platt R, Black S, Shinefield H, Chen RT, Epidemiology 2005 16 3 336 341 10.1097/01.ede.0000155506.05636.a4 15824549 (Pubitemid 40590071)
2. Early detection of adverse drug events within population-based health networks: application of sequential testing methods. Brown JS, Kulldorff M, Chan KA, Davis RL, Graham D, Pettus PT, Andrade SE, Raebel MA, Herrinton L, Roblin D, Boudreau D, Smith D, Gurwitz JH, Gunter MJ, Platt R, Pharmacoepidemiol Drug Saf 2007 16 12 1275 1284 10.1002/pds.1509 17955500 (Pubitemid 350303439)
3. Vaccine Safety Datalink Rapid Cycle Analysis Team Real-Time vaccine safety surveillance for the early detection of adverse events. Lieu TA, Kulldorff M, Davis RL, Lewis EM, Weintraub E, Yih K, Yin R, Brown JS, Platt R, Med Care 2007 45 10 89 S95 17909389
4. Estimating causal effects from large data sets using the propensity score. Rubin DB, Ann Intern Med 1997 127 757 763 10.7326/0003-4819-127-8-Part-2- 199710151-00064 9382394 (Pubitemid 27446562)
5. Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Stürmer T, Schneeweiss S, Brookhart MA, Rothman KJ, Avorn J, Glynn RJ, Am J Epidemiol 2005 161 9 891 898 10.1093/aje/kwi106 15840622 (Pubitemid 40577844)
6. A review of applications of propensity score methods showed increased use but infrequently different estimates compared with other methods. Stürmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S, J Clin Epidemiol 2006 59 437 447 16632131
7. Indications for propensity scores and review of their use in pharmacoepidemiology. Glynn RJ, Schneeweiss S, Stürmer T, Basic Clin Pharmacol Toxicol 2006 98 253 259 10.1111/j.1742-7843.2006.pto-293.x 16611199
8. The use of propensity scores in pharmacoepidemiologic research. Perkins SM, Tu W, Underhill MG, Zhou XH, Murray MD, Phamacoepidemiol Drug Saf 2000 9 93 101 10.1002/(SICI)1099-1557(200003/04)9:2<93:AID-PDS474>3.0.CO;2-I (Pubitemid 30307349)
9. Estimating exposure effects by modeling the expectation of exposure conditional on confounders. Robins JM, Mark SD, Newey WK, Biometrics 1992 48 479 495 10.2307/2532304 1637973
10. On principles for modeling propensity score in medical research. Rubin DB, Phamacoepidemiol Drug Saf 2005 14 227 238 10.1002/pds.986 (Pubitemid 40528852)
11. Variable selection for propensity score models. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Stürmer T, Am J Epidemiol 2006 163 12 1149 1156 10.1093/aje/kwj149 16624967 (Pubitemid 43987579)
12. Quantifying biases in causal models: classical confounding vs. collider-stratification bias. Greenland S, Epidemiology 2003 14 3 300 306 12859030 (Pubitemid 40417081)
13. Confounding control in healthcare database research: challenges and potential approaches. Brookhart MA, Stürmer T, Glynn RJ, Rassen J, Schneeweiss S, Med Care 2010 48 6 114 S120 20473199
14. Use of propensity score technique to account for exposure-related covariates: an example and lesson. Seeger JD, Kurth T, Walker AM, Med Care 2007 45 143 S148 10.1097/MLR.0b013e318074ce79 17909373
15. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy. Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger JD, Pharmacoepidemiol Drug Saf 2007 16 504 512 10.1002/pds.1356 17245800 (Pubitemid 46824271)
16. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA, Epidemiology 2009 20 4 512 522 10.1097/EDE. 0b013e3181a663cc 19487948
17. Performance of a semi-automated approach for risk estimation using a common data model for longitudinal healthcare databases. Le VH, Beach JK, Powell G, Pattishall E, Ryan P, Mera RM, Stat Methods Med Res 2013 22 1 97 112 10.1177/0962280211403599 21680614
18. Confounding adjustment via a semiautomated highdimensional propensity score algorithm: an application to electronic medical records. Toh S, Rodríguez AGL, Hernán AM, Pharmacoepidemiology and drug safety 2011 20 849 857 10.1002/pds.2152 21717528
19. Spurious effects from an extraneous variable. Bross ID, J Chronic Dis 1966 19 6 637 647 10.1016/0021-9681(66)90062-2 5966011
20. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Brookhart MA, Wang PS, Solomon DH, Schneeweiss S, Epidemiology 2006 17 3 268 275 10.1097/01.ede.0000193606.58671.c5 16617275
21. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial Celecoxib Long-term Arthritis Safety Study. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS, JAMA 2000 284 10 1247 1255 10.1001/jama.284.10.1247 10979111
22. Triadafilopoulos G; SUCCESS-I Investigators Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, Andrade-Ortega L, Wallemark C, Agrawal NM, Eisen GM, Stenson WF, Am J Med 2006 119 3 255 266 10.1016/j.amjmed.2005.09.054 16490472 (Pubitemid 43255067)
23. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. Deeks JJ, Smith LA, Bradley MD, BMJ 2002 325 7365 619 10.1136/bmj.325.7365.619 12242171
24. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Moore RA, Derry S, Makinson GT, McQuay HJ, Arthritis Res Ther 2005 7 3 644 R665 10.1186/ar1704 15899051
25. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, Verburg KM, Geis GS, Am J Gastroenterol 2000 95 7 1681 1690 10.1111/j.1572-0241.2000.02194.x 10925968 (Pubitemid 30485002)
26. Significant upper gastrointestinal events associated with conventional NSAID versus celecoxib. Goldstein JL, J Rheumatol Suppl 2000 60 25 28 11032099
27. Evaluating medication effects outside of clinical trials: new-user designs. Ray WA, Am J Epidemiol 2003 158 9 915 920 10.1093/aje/kwg231 14585769 (Pubitemid 37323253)
28. MarketScan§ssup§®§esup§ Commercial Claims and Encounters of Thomson Reuters Healthcare. 2011 [http://thomsonreuters.com/ products-services/healthcare/healthcare-products/a-z/marketscan-research- analytics/]
29. Positive predictive value of ICD-9 codes in the identification of cases of complicated peptic ulcer disease in the Saskatchewan hospital automated database. Raiford DS, Perez Gutthann S, Garcia Rodriguez LA, Epidemiology 1996 7 101 104 10.1097/00001648-199601000-00018 8664388 (Pubitemid 26003854)
30. The Anatomical Therapeutic Chemical (ATC) classification. 2012 [http://www.whocc.no/]
31. The American Academy of Ophthalmology Adopts SNOMED CT as Its Official Clinical Terminology. Hoskins H Jr, Hildebrand P, Lum F, Ophthalmology 2008 115 2 225 226 10.1016/j.ophtha.2007.11.026 18243903 (Pubitemid 351163391)
32. Clinical Classifications Software (CCS) for ICD-9-CM. 2012 [http://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp]
33. Risk of upper gastrointestinal bleeding and perforation associated with individual nonsteroidal antiinflammatory drugs. García Rodríguez LA, Jick H, Lancet 1994 343 769 772 10.1016/S0140-6736(94)91843-0 7907735 (Pubitemid 24098698)
34. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Gutthann SP, García Rodríguez LA, Raiford DS, Epidemiology 1997 8 18 24 10.1097/00001648- 199701000-00003 9116088 (Pubitemid 27014216)
35. Association between nonsteroidal antiinflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. HernándezDíaz S, García Rodríguez LA, Arch Intern Med 2000 160 2093 2099 10.1001/archinte.160.14. 2093 10904451 (Pubitemid 30482713)
36. Problems due to small samples and sparse data in conditional logistic regression analysis. Greenland S, Schwartzbaum JA, Finkle WD, Am J Epidemiol 2000 151 5 531 539 10.1093/oxfordjournals.aje.a010240 10707923 (Pubitemid 30471029)
37. A simulation study of the number of events per variable in logistic regression analysis. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR, J Clin Epidemiol 1996 49 12 1373 1379 10.1016/S0895-4356(96)00236-3 8970487 (Pubitemid 27028925)
38. Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples. Rassen JA, Glynn JR, Brookhart MA, Schneeweiss S, Am J Epidemiol 2011 173 12 1404 1413 10.1093/aje/kwr001 21602301